Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus-based steroid avoidance after renal transplantation: alemtuzumab versus basiliximab + mycophenolate mofetil
2006-000830-11Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Apr 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab, basiliximab, tacrolimus and mycophenolate mofetil in kidney transplant immunosuppression (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: DTPA isotopic glomerular filtration rate. Started Apr 2006; status: completed.
02
Drugs
alemtuzumabbasiliximabtacrolimusmycophenolate mofetil
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2006-000830-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000830-11.